Goldman Sachs Group Inc Obs Eva Sa Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	BUY	$0.14 - $1.83 $402 - $5,255	2,872 Added 10.06%	31,421 $4,000
Q3 2022 Nov 10, 2022	BUY	$0.14 - $1.83 $402 - $5,255	2,872 Added 10.06%	31,421 $0
Q2 2022 May 14, 2024	BUY	$1.34 - $2.08 $38,255 - $59,381	28,549 New	28,549 $46,000
Q2 2022 Aug 15, 2022	SELL	$1.34 - $2.08 $2,438 - $3,785	-1,820 Reduced 5.99%	28,549 $46,000
Q1 2022 May 16, 2022	BUY	$1.1 - $2.17 $4,590 - $9,055	4,173 Added 15.93%	30,369 $46,000
Q4 2021 Feb 14, 2022	SELL	$1.99 - $3.1 $129,947 - $202,430	-65,300 Reduced 71.37%	26,196 $52,000
Q3 2021 Nov 10, 2021	BUY	$2.47 - $3.34 $225,995 - $305,596	91,496 New	91,496 $285,000

88K

Ticker OBSV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,499,200
Description
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometrio...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.